Continuum
Innovative
Life Sciences Division

Intellectual Property

Three Decades ofSustained Innovation

Intellectual property is the visible record of an evolving scientific platform. Read from top to bottom, the timeline below traces the program's continuous trajectory — from early follicular biology and the founding HairGenesis® formulation, through global commercialization and category-defining peer-reviewed milestones, into the current Continuum platform and its active USPTO provisional portfolio.

Platform Evolution

  1. Era IEarly 1990s — 2002

    Foundational follicular biology

    Early work in follicular pharmacology and the formulation chemistry that would become HairGenesis® — culminating in the first randomized, double-blind, placebo-controlled clinical trial of botanical 5α-reductase inhibition in androgenetic alopecia.

    • platform

      HairGenesis® — founding formulation platform

    • publication

      Prager, Bickett, French, Marcovici — JACM 8(2):143–152

      2002 · First-in-field Level-1 evidence

  2. Era II2003 — 2011

    Inflammatory reframing of AGA

    Genome-wide transcriptomic work in keratinocytes — in collaboration with the SUNY Center for Functional Genomics — reframed androgenetic alopecia as a partly inflammatory disease and introduced multi-target, anti-inflammatory follicular therapy to the peer-reviewed record.

    • publication

      Chittur, Parr, Marcovici — Evid. Based Complement. Alt. Med.

      2011 · Whole-genome anti-inflammatory dataset

  3. Era III2013 — 2018

    Global commercialization & comparator biology

    Worldwide commercialization of HairGenesis® through Monrone as the program's primary GCC commercialization partner — combined with parallel bench work showing that a defined multi-component botanical composition could outperform finasteride on androgen-axis biomarkers in matched dermal-papilla and LNCaP assays.

    • platform

      Monrone — primary GCC commercialization partner

    • publication

      Marcovici et al. — Phytotherapy Research (Wiley)

      2016 · Outperformed finasteride at the bench

  4. Era IV2019 — 2022

    Nano-delivery & TrichoCyte® platform

    Translation of the program into a β-cyclodextrin inclusion-complex nano-delivery architecture — published as a clinical case series and protected as proprietary platform chemistry that has since seen broad category emulation under generic 'nano-encapsulated' marketing language.

    • platform

      TrichoCyte® — nano-inclusion delivery platform

    • publication

      Marcovici & Bauman — Cosmetics 7(3):65

      2020 · First clinical use of β-cyclodextrin inclusion delivery in AGA

  5. Era V2023 — present

    Continuum platform · current IP portfolio

    The current Continuum Innovative platform — a unified, hypothesis-driven framework spanning intracrine regulation, immune privilege, multi-nodal stability, senescence biology, and menopause-associated follicular destabilization. Five active USPTO provisional applications anchor the portfolio; a cryo-CO₂ amplification approach is the subject of ongoing collaborative exploration.

Active USPTO Provisional Portfolio

Five concurrent provisional applications protecting the current Continuum platform.

Select any provisional below to open its illustrated deep-dive.

01

Progressive Autoimmune Loss of Privilege

USPTO Provisional

64/065,059

  • Immune privilege
  • Follicular territorial integrity
  • Antigen suppression
02

Intracrine Structure–Function Dynamics

USPTO Provisional

64/063,263

  • Intracrine regulation
  • Local androgen metabolism
  • Pleiotropic signaling
03

Coordinated Multi-Nodal Stabilization

USPTO Provisional

64/069,570

  • Multi-nodal stabilization
  • Phenotype architecture
  • Integrated signaling
04

Senescence Biology

USPTO Provisional

64/073,264

  • Cellular senescence
  • Regenerative competence
  • Follicular aging
05

Menopause-Associated Follicular Destabilization

USPTO Provisional

64/095,147

  • Menopausal transition
  • Endocrine-follicular axis
  • Destabilization reversal

Provisional application numbers indicate active innovation themes currently under evaluation. Formal patent application status and prosecution details are managed under appropriate confidentiality.

Contact